Parkinson DiseasePhase 2NCT02687542
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
A Phase 2 study testing PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD) and PF-06649751 middle dose 2 (7 mg QD) in people with Parkinson Disease, run by Pfizer at 57 sites in 6 countries.
Trial summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations. Read more about this study
- Who is it for?
- Ages 40 to 85 years
- Conditions the study is for
- Parkinson Disease
- What is being tested?
- PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD) and PF-06649751 middle dose 2 (7 mg QD)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 108 participants
- Where
- 57 sitesin 6 countries
- Study dates
- 3 Mar 2016to 10 Nov 2017
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Females of non-childbearing potential and/or male subjects between the ages of 40 and 85 years, inclusive.
- Clinical diagnosis of Parkinson's disease.
- Able to refrain from any Parkinson's disease medication not permitted by the protocol.
Who cannot join
- Female of childbearing potential
- History or presence of atypical Parkinsonian syndrome.
- History of surgical intervention for Parkinson's disease.
- Severe acute or chronic medical or psychiatric condition or laboratory abnormality.
- Any condition possibly affecting drug absorption.
- Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.
Trial locations and contacts
57 sites in 6 countries.
57 sites in 6 countries
United States33 sites
Dent Neurologic Institute
Amherst, New York, 14226
Dent Neurosciences Research Center ,Inc. DBA Dent Neurologic Institute
Amherst, New York, 14226
Arcadia Neurology Center
Arcadia, California, 91006
Atlanta Center for Medical Research
Atlanta, Georgia, 30331
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, 33486
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Rush University Medical Center
Chicago, Illinois, 60612
Cleveland Clinic
Cleveland, Ohio, 44195
Duke University Medical center
Durham, North Carolina, 27705
Duke University/Duke Neurology/Department of Neurology
Durham, North Carolina, 27705
Associated Neurologists of Southern Connecticut, PC
Fairfield, Connecticut, 06824
University of Florida Center for Movement Disorders and Neurorestoration
Gainesville, Florida, 32607
AS Clinical Research Consultants of North Texas, PLLC
Greenville, Texas, 75401
Baylor College of Medicine
Houston, Texas, 77030
Indiana University Health Neuroscience Center
Indianapolis, Indiana, 46202
Booth Gardner Parkinson's Care Center
Kirkland, Washington, 98034
Faculty Physicians and Surgeons of Loma Linda University School of Medicine
Loma Linda, California, 92354
CRI Worldwide, LLC
Marlton, New Jersey, 08053
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92658
Hoag Memorial Hospital
Newport Beach, California, 92663
Dent Neurologic Institute
Orchard Park, New York, 14127
Neurology Associates of Ormond Beach
Ormond Beach, Florida, 32174
SC3 Research Group, Inc
Pasadena, California, 91105
Xenoscience, Inc
Phoenix, Arizona, 85004
St Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013
Rhode Island Hospital/ Brown University Medical School
Providence, Rhode Island, 02903
Wake Research Associates, LLC
Raleigh, North Carolina, 27612
University of South Florida
Tampa, Florida, 33613
University of Toledo
Toledo, Ohio, 43614
Neurosearch-Torrance
Torrance, California, 90505
The Movement Disorder Clinic of Oklahoma
Tulsa, Oklahoma, 74136
Vero Beach Neurology and Research Institute
Vero Beach, Florida, 32960
Abington Neurological Associates, Ltd.
Willow Grove, Pennsylvania, 19090
France6 sites
CHU de Grenoble Alpes
Grenoble, 38043 Cedex 9
CHU de Grenoble Alpes
La Tronche, 38700
CHRU de Lille-Hopital Roger Salengro
Lille, 59037 cedex
Hopital de la Timone APHM
Marseille, 13385 cedex 05
Hopital de La Timone
Marseille, 13385 cedex 05
Hopital La Pitie-Salpetriere
Paris, 75013
Spain6 sites
Hospital Clinic i Provincial de Barcelona
Barcelona, 08036
Policlinica de Guipuzcoa
Donostia / San Sebastian, Guipuzcoa, 20009
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, 08907
Hospital Universitario de la Princesa
Madrid, 28006
Hospital Clinico Universitario
Santiago de Compostela, A Coruna, 15706
Hospital Universitario y Politecnico la Fe
Valencia, 46026
Germany5 sites
St. Josef-Hospital GmbH
Bochum, 44791
Universitaetsklinikum Carl Gustav Carus Klinik und Poliklinik fur Neurologie
Dresden, 01307
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, 79106
Klinikum rechts der Isar der Technischen Universitaet Muenchen
München, 81675
Universitaetsklinik Ulm
Ulm, 89081
Japan5 sites
Asahikawa Medical center
Asahikawa, Hokkaido, 0708644
Juntendo University Hospital
Bunkyo-ku, Tokyo, 113-8431
Tazuke Kofukai Medical Research Institute Kitano Hospital
Kita-ku, Osaka, 530-8480
Medical Corporation Abe Neurology Clinic
Morioka, Iwate, 020-0878
Osaka University Hospital
Suita, Osaka, 565-0871
Canada2 sites
Montreal Neurological Hospital Research Pharmacy
Montreal, Quebec, H3A 2B4
Montreal Neurological Institute and Hospital
Montreal, Quebec, H3A 2B4
About this study
Official title: A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
Read the detailed description
The study has a randomized, double-blind, placebo-controlled parallel group design. Approximately 198 subjects will be randomized to 5 treatment groups. Each subject will participate in the study for approximately 23 weeks including a 30 day screening period, 15 week double blind treatment period, and an approximately 28 day follow-up period.
- Conditions
- Parkinson Disease
- Being tested
- Placebo, PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD), PF-06649751 middle dose 2 (7 mg QD), PF-06649751 high dose (15 mg QD)
- Keywords
- Parkinson Disease, Motor Fluctuation
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDrug
Placebo
PF-06649751 low dose (1 mg QD)Drug
PF-06649751 low dose (1 mg QD)
PF-06649751 middle dose 1 (3 mg QD)Drug
PF-06649751 lower middle dose 1 (3 mg QD)
PF-06649751 middle dose 2 (7 mg QD)Drug
PF-06649751higher middle dose 2 (7 mg QD)
PF-06649751 high dose (15 mg QD)Drug
PF-06649751 high dose (15 mg QD)
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Placebo Receives: Drug: Placebo |
| PF-06649751 low dose (1 mg QD) | Experimental | PF-06649751 low dose level (1 mg QD) Receives: Drug: PF-06649751 low dose (1 mg QD) |
| PF-06649751 middle dose 1 (3 mg QD) | Experimental | PF-06649751 lower middle dose 1 (3 mg QD) Receives: Drug: PF-06649751 middle dose 1 (3 mg QD) |
| PF-06649751 middle dose 2 (7 mg QD) | Experimental | PF-06649751 higher middle dose 2 (7 mg QD) Receives: Drug: PF-06649751 middle dose 2 (7 mg QD) |
| PF-06649751 high dose (15 mg QD) | Experimental | PF-06649751 high dose (15 mg QD) Receives: Drug: PF-06649751 high dose (15 mg QD) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Daily OFF Time at Week 10
A paper Hauser diary was utilized to record motor state for half-hour intervals. Participants completed the diary by answering whether they had been OFF for 3 consecutive days in the week prior to each visit (except Day 28 visit), including 3 consecutive days during the week prior to Day 0 (Randomization).
The daily OFF time was calculated as the average of the 3 consecutive daily OFF hours from the Hauser diary at each visit.
Measured: Week 10; Baseline was defined as the average daily OFF time (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit day 0).
Secondary outcomes (12)
Change From Baseline in Daily OFF Time
A paper Hauser diary was utilized to record motor state for half hour intervals. Participants completed the diary by answering whether they had been OFF for 3 consecutive days in the week prior to each visit (except Day 28 visit), including 3 consecutive days during the week prior to Day 0 (Randomization).
The daily OFF time was calculated as the average of the 3 consecutive daily OFF hours from the Hauser diary at each visit.
Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.
Measured: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily OFF time (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit day 0).
Change From Baseline in Daily ON Time With Troublesome Dyskinesia
A paper Hauser diary was utilized to record motor state for half hour intervals. The participants answered the Hauser diary on whether they had been ON with troublesome dyskinesia. A diary day started with the interval 24:00-0:30 through 23:30-24:00 on each chronological day for 3 consecutive days. On the days recording the home diary, participants made an entry every 30 minutes during their normal waking time and upon awakening from time asleep.
The daily ON hours was calculated as the average of the 3 consecutive daily ON hours from the Hauser diary at each visit.
Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.
Measured: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily ON time with Troublesome Dyskinesia (using 3 Hauser patient diary Days) prior to Day -1 (study derived day and equalled to nominal visit Day 0).
Change From Baseline in Daily ON Time Without Troublesome Dyskinesia
A paper Hauser diary was utilized to record motor state for half hour intervals. The participants answered the Hauser diary on whether they had been ON without troublesome dyskinesia. A diary day started with the interval 24:00-0:30 through 23:30-24:00 on each chronological day for 3 consecutive days. On the days recording the home diary, participants made an entry every 30 minutes during their normal waking time and upon awakening from time asleep.
The daily ON hours was calculated as the average of the 3 consecutive daily ON hours from the Hauser diary at each visit.
Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.
Measured: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily ON time without Troublesome Dyskinesia (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit Day 0)
Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
MDS-UPDRS Part III assessed the motor signs of Parkinson's disease and was administered by the investigator. It was comprised of 33 sub-scores based on 18 items, several with right, left or other body distribution scores. Each question was anchored with 5 responses that were linked to commonly accepted clinical terms: 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. If more than 7 of the Part III items were missing, the score for that time point was missing, otherwise MDS-UPDRS Part III score was imputed as sum of the non-missing items*(total number of items)/ (number of items non-missing). The MDS-UPDRS Part III total score range is 0-132. Higher score indicated more severe motor signs of Parkinson's disease.
Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.
Measured: Weeks 1, 2, 3, 4, 5, 10 and 15; Baseline was defined as the Day -1 (study derived day and equalled to nominal visit Day 0) measurement
Change From Baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, IV, and Total Score
Each question of Part I,II or IV with 5 responses was linked to the same clinical terms as Part III.The score was missing if more than 7 items were missing for a time point; otherwise Part I,II or IV score was imputed as sum of non-missing items*(total number of items)/(number of items non-missing).•PartI (Non-Motor Aspects of Experiences of Daily Living) assessed non-motor experiences of daily living using 13questions(Range:0-52).•PartII(Motor Aspects of Experiences of Daily Living) assessed motor experiences of daily living using 13questions(Range:0-52).•PartIV(Motor Complications) assessed motor complications,dyskinesias, and motor fluctuations using historical and objective information with 6questions(Range:0-24).•MDS-UPDRS Total Score:the sum of Parts I,II,III,and IV(Range:0-260).Higher score indicated more severe motor signs of Parkinson's disease.Week15's results were interpreted cautiously given almost half participants were not available for the analysis as compared to Week10
Measured: Weeks 5, 10 and 15; Baseline was defined as the Day -1 (study derived day and equalled to nominal visit Day 0) measurement
Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality
The safety laboratory tests including Hematology, Clinical Chemistry and Urinalysis were performed.
Determination if there were any laboratory data abnormalities of potential clinical concern was based on Pfizer Data Standards.
Incidence of laboratory test abnormalities (without regard to baseline abnormality) was summarized within each treatment group.
Measured: Baseline (Day 0) to Week 17
Number of Participants With Vital Sign Results Meeting the Criteria for Categorical Summarization
Vital Signs including blood pressure and pulse rate were measured. Vital signs were collected first while the participant was in the supine position and then in the standing position.
Measured: Baseline (Day 0) to Week 17
Number of Participants With Electrocardiogram (ECG) Results Meeting the Criteria for Categorical Summarization
The average of the triplicate readings of ECG data was collected at each assessment time.
Number of participants with ECG results meeting the criteria for categorical summarization for time from the beginning of the P wave until the beginning of the QRS complex (PR Interval), time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS Duration), time between the start of the Q wave and the end of the T wave in the heart's electrical cycle (QT Interval) and corrected QT (Fridericia correction) (QTcF Interval) were presented.
Measured: Baseline (Day 0) to Week 17
Number of Participants With Suicidal Ideation Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS) at Post-baseline Visits
The Columbia Suicide Severity Rating Scale (C-SSRS) was an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS responses were mapped to the C-CASA. There were 3 key endpoints for suicidality data analysis and evaluation:
- Suicidal Behavior: A participant was said to have suicidal behavior if the participant had experienced completed suicide / suicide attempt / reparatory acts toward imminent suicidal behavior.
- Suicidal Ideation: Any observed suicidal ideation mapped to a single C-CASA category.
- Suicidal Behavior or Ideation (participants with new onset suicidality): A participant was considered to have a new onset of suicidality if the participant reported no ideation and no behavior at the baseline assessment and reported any behavior or ideation post-baseline. Data observed at screening was not considered in the definition of worsening.
Measured: Days 0 (Baseline), 7, 14, 21, 28, 35, 70, 77, 84, 91, 105 and 119
Change From Baseline in Total Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)
The QUIP-RS was a brief, patient reported outcome measure designed to assess the severity of symptoms of Impulsive-Compulsive Disorders (ICDs) and related behaviors reported to occur in Parkinson's disease.
The QUIP-RS assessed 7 disorders (Gambling, Sex, Buying, Eating, Hobbyism-punding [performing tasks and repeating activities] and Taking medications). If more than 5 items were missing, the total QUIP-RS score was set as missing; otherwise, the total QUIP-RS score was imputed as follows: sum of the non-missing item scores * (total number of items) / (number of items non-missing). The higher score indicated a greater level of the ICD.
The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112.
Measured: Baseline (Day 0) and Weeks 5, 10 and 15
Total Physician Withdrawal Checklist (PWC-20) on Days 105 and 119, and Change From Day 105 to Day 119
The PWC-20 is a physician completed, 20 item reliable and sensitive instrument for the assessment of discontinuation symptoms. The PWC-20 was collected after the completion of study treatment and also at the first visit of follow-up.
The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. If more than 5 items were missing, the total PWC-20 score was missing; otherwise, the total PWC-20 score was imputed as follows: sum of the non-missing items * (total number of items) / (number of items non-missing). The higher score indicated more frequent/severe symptoms.
Measured: Days 105 and 119
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths
An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event did not need necessarily to have a causal relationship with the treatment or usage.
An SAE was any untoward medical occurrence at any dose that:
- Resulted in death;
- Was life threatening (immediate risk of death);
- Required inpatient hospitalization or prolongation of existing hospitalization;
- Resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions);
- Resulted in congenital anomaly/birth defect.
Measured: Day 1 to follow-up (Week 19 visit)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Feb 2016 (estimated)
- Study start3 Mar 2016
- Primary completion10 Nov 2017
- Study completion10 Nov 2017
Why it stopped: Terminated 25Sep17 due to insufficient efficacy. Not due to safety reasons.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 108 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02687542
- Sponsor's protocol ID
- B7601003
- Other IDs
- 2015-004912-39, A-ROSE PD, A-ROSE, 2015
- Status last verified
- Oct 2020
- First submitted
- 29 Jan 2016
- Last updated
- 23 Nov 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Study at a glance
From the registry record, last updated by the sponsor on 23 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE
- ClinicalTrials.gov ID
- NCT02687542
- Acronym / sponsor ID
- B7601003
- Conditions
- Parkinson Disease
- Keywords
- Parkinson Disease, Motor Fluctuation
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Terminated 25Sep17 due to insufficient efficacy. Not due to safety reasons.
- Enrolment
- 108 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 3 Mar 2016 (actual)
- Primary completion
- 10 Nov 2017 (actual)
- Study completion
- 10 Nov 2017 (actual)
- First posted
- 22 Feb 2016 (estimated)
- Results
- Posted 24 Dec 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
Detailed description
The study has a randomized, double-blind, placebo-controlled parallel group design. Approximately 198 subjects will be randomized to 5 treatment groups. Each subject will participate in the study for approximately 23 weeks including a 30 day screening period, 15 week double blind treatment period, and an approximately 28 day follow-up period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: PlaceboPlacebo |
| PF-06649751 low dose (1 mg QD) | Experimental | Drug: PF-06649751 low dose (1 mg QD)PF-06649751 low dose level (1 mg QD) |
| PF-06649751 middle dose 1 (3 mg QD) | Experimental | Drug: PF-06649751 middle dose 1 (3 mg QD)PF-06649751 lower middle dose 1 (3 mg QD) |
| PF-06649751 middle dose 2 (7 mg QD) | Experimental | Drug: PF-06649751 middle dose 2 (7 mg QD)PF-06649751 higher middle dose 2 (7 mg QD) |
| PF-06649751 high dose (15 mg QD) | Experimental | Drug: PF-06649751 high dose (15 mg QD)PF-06649751 high dose (15 mg QD) |
Who may qualify
- Ages
- 40 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Females of non-childbearing potential and/or male subjects between the ages of 40 and 85 years, inclusive.
- Clinical diagnosis of Parkinson's disease.
- Able to refrain from any Parkinson's disease medication not permitted by the protocol.
Key exclusion criteria (6 listed)
- Female of childbearing potential
- History or presence of atypical Parkinsonian syndrome.
- History of surgical intervention for Parkinson's disease.
- Severe acute or chronic medical or psychiatric condition or laboratory abnormality.
- Any condition possibly affecting drug absorption.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboPlacebo | Drug | Placebo |
| PF-06649751 low dose (1 mg QD)PF-06649751 low dose (1 mg QD) | Drug | PF-06649751 low dose (1 mg QD) |
| PF-06649751 middle dose 1 (3 mg QD)PF-06649751 lower middle dose 1 (3 mg QD) | Drug | PF-06649751 middle dose 1 (3 mg QD) |
| PF-06649751 middle dose 2 (7 mg QD)PF-06649751higher middle dose 2 (7 mg QD) | Drug | PF-06649751 middle dose 2 (7 mg QD) |
| PF-06649751 high dose (15 mg QD)PF-06649751 high dose (15 mg QD) | Drug | PF-06649751 high dose (15 mg QD) |
Primary outcome
Change From Baseline in Daily OFF Time at Week 10
Time frame: Week 10; Baseline was defined as the average daily OFF time (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit day 0).
A paper Hauser diary was utilized to record motor state for half-hour intervals. Participants completed the diary by answering whether they had been OFF for 3 consecutive days in the week prior to each visit (except Day 28 visit), including 3 consecutive days during the week prior to Day 0 (Randomization). The daily OFF time was calculated as the average of the 3 consecutive daily OFF hours from the Hauser diary at each visit.
12 secondary outcomes
Change From Baseline in Daily OFF Time
Time frame: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily OFF time (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit day 0).
Change From Baseline in Daily ON Time With Troublesome Dyskinesia
Time frame: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily ON time with Troublesome Dyskinesia (using 3 Hauser patient diary Days) prior to Day -1 (study derived day and equalled to nominal visit Day 0).
Change From Baseline in Daily ON Time Without Troublesome Dyskinesia
Time frame: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily ON time without Troublesome Dyskinesia (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit Day 0)
Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
Time frame: Weeks 1, 2, 3, 4, 5, 10 and 15; Baseline was defined as the Day -1 (study derived day and equalled to nominal visit Day 0) measurement
Change From Baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, IV, and Total Score
Time frame: Weeks 5, 10 and 15; Baseline was defined as the Day -1 (study derived day and equalled to nominal visit Day 0) measurement
Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality
Time frame: Baseline (Day 0) to Week 17
Number of Participants With Vital Sign Results Meeting the Criteria for Categorical Summarization
Time frame: Baseline (Day 0) to Week 17
Number of Participants With Electrocardiogram (ECG) Results Meeting the Criteria for Categorical Summarization
Time frame: Baseline (Day 0) to Week 17
Number of Participants With Suicidal Ideation Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS) at Post-baseline Visits
Time frame: Days 0 (Baseline), 7, 14, 21, 28, 35, 70, 77, 84, 91, 105 and 119
Change From Baseline in Total Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)
Time frame: Baseline (Day 0) and Weeks 5, 10 and 15
Total Physician Withdrawal Checklist (PWC-20) on Days 105 and 119, and Change From Day 105 to Day 119
Time frame: Days 105 and 119
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths
Time frame: Day 1 to follow-up (Week 19 visit)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Nov 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
57 sites in 6 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD) and PF-06649751 middle dose 2 (7 mg QD) in people with Parkinson Disease, run by Pfizer at 57 sites in 6 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 23 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 57 sites in United States, France, Spain, Germany, Japan and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 24 Dec 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Daily OFF Time at Week 10 (time frame: Week 10; Baseline was defined as the average daily OFF time (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit day 0).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Nov 2020.